ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Sharon Choi discussing comprehensive genomic profiling of Black and non-Hispanic White men with prostate cancer. Racial ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

BY DR. AMANI JAMBHEKARCHRISTUS St. Vincent Specialists ClinicLos Alamos My name is Amani Jambhekar and I’m a breast cancer and melanoma surgeon in Santa Fe, NM. I’m also certified in Cancer ...

The study adds to growing evidence that digital tools can maximize genetic counselors' limited time without patient harm.

Researchers have identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form. The gene can be indirectly targeted with an ...

A new artificial intelligence (AI) test can identify which men with prostate cancer will benefit most from the life-extending ...

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...

The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC) ...

Scientists say they have worked out a machine learning method with the ability to provide close to precise survival estimates ...

Johnson & Johnson (JNJ) posts Phase 3 trial win for Akkega plus prednisone in metastatic castration-sensitive prostate cancer ...